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TheobjectivewastoanalyzetheresultsofUG-FNAB,performedinunselectedconsecutivepatientswiththyroidnodules.Methods.
The UG-FNAB records were analyzed in this retrospective study. Indication for biopsy was the presence of at least one nodule
detected by ultrasound. Results. 330 patients at mean age ± SD 48.4 ± 11.2 years; women/men = 12.8/1 were analyzed. From
the total 596 nodules found 546 (91.6%) were investigated with 1231 punctures (2.3 per nodule and 3.7 per patient). Benign
solitary nodules had 42.7%, multinodular goiter (MNG) 44.8%, inconclusive 4.8%, and others 2.1% and malignant nodules 5.5%
of the patients (6.6% of solitary and 5.1% of MNG patients). The risk for a separate nodule in MNG to be malignant was 2.7%.
Conclusions. UG-FNAB is a safe and reliable diagnostic approach for thyroid nodules. It is the method of choice for hypo- and
isoechoic not purely cystic solitary nodules, regardless of the nodule size. In MNG, its positive predictive value and diagnostic
accuracy are lower. The ﬁnal decision for regular US monitoring, UG-FNAB of the dominant nodule, multipuncture UG-FNAB
or surgical exploration is one of complex appraisal. We consider UG-FNAB appropriate for most nodules in MNG, according to
the above mentioned criteria.
1.Introduction
Diﬀerentiated thyroid cancer is among the most rapidly
increasing types of cancers with an incidence that has
doubled in the past 15 years [1]. Ultrasonography (US)
is the commonly used imaging technique for the thyroid
gland. However, noninvasive diﬀerentiating benign from
malignant lesions with clinically certainty is impossible even
with modern equipment used by experienced specialists.
A predominantly solid nodule, hypoechogenicity, micro-
calciﬁcation, ill-deﬁned margins, intranodular vascularity,
and taller-than-wide shape have all been associated with
increased risk of malignancy, but no single US characteristic
is suﬃciently sensitive or speciﬁc to exclude or diagnose
malignancy by itself. However, the use of combinations of
US characteristics to stratify nodules into high- and low-risk
for malignancy appears a promising strategy. [2].
More attention is paid to the vascular investigations.
Color ﬂow Doppler sonography (CFDS) and power Doppler
are promising noninvasive methods. Some studies did
not show any improvement in diagnostic accuracy and
malignancy-predictive value for CFDS [3–6], but others sug-
gested that Doppler is helpful [7–11], especially when using
the second generation ultrasonographic contrast agents [12].
Recently, Sancak et al. compared CFDS and microvessel
density determined by CD34-antibody staining and con-
cluded that even the assessment of only the intranodular
vascularization detected by CFDS does not result in a better
discrimination of benign and malignant nodules nor does
it give a better correlation with the histologic density of
small vessels and microvessels. The authors also suggested
that power Doppler technique may be helpful to show small
vessels [13]. Moon et al. in a retrospective study using
power Doppler ultrasonography reported that vascularity
itself or a combination of vascularity and gray-scale US
features was not as useful as the use of suspicious gray-
scale US features alone for predicting thyroid malignancy
[14]. While occasionally useful in selecting nodules for
ultrasound-guided ﬁne-needle aspiration biopsy (UG-FNA),
color Doppler US should not be considered a requirement
for the selection of nodules for sampling [15].2 ISRN Endocrinology
Table 1: Malignant nodules, detected by cytology.
Cytology N of patients
Papillary 8








Fine-needle aspiration biopsy (FNAB) is routinely used
to evaluate nodular thyroid disease. But the results of blind
FNAB are often inconclusive, especially in cystic or mixed
nodules. A combination of both methods by-UG-FNAB
increases the diagnostic power of each of these methods
(ultrasound and FNAB) and is costeﬀective as a ﬁrst-line
diagnostic procedure in patients with thyroid nodules [16–
20]. Although broadly recognized as a method of choice for
thyroid nodules, opinions still diﬀer as to its use for other
indications [1].
Thyroid nodules are estimated to be present in 20%
or more of adults who are screened by routine thyroid
echography [20]. The reported prevalence of nodules dif-
fers according to the population studied, with the most
important determinants being age and iodine status. The
prevalence of malignant lesions also varies. Most studies
using the US technique are based on “retrograde analysis”;
that is, they work back from morphologic results and
analyze the coincidence with the numbers of lesions already
diagnosed by cytology, FNAB and ultrasound. Specimens
are usually preselected from the ultrasound and clinically
suspicious lesions. Studies that evaluate the malignancy
potential of every nodule either solitary or in the multin-
odular goiter (MNG) are rare. A recent consensus statement
about the management of thyroid nodules detected at US
[15] identiﬁed several important unanswered questions that
merit future research. One of them is: In a patient with
multiple nodules, which and how many nodules should
undergo UG-FNAB?
The Aim. of this study was to analyze the results of UG-
FNAB from 330 unselected consecutive patients with thyroid
nodules.
2. Patientsand Methods
The observational period in this retrospective study was
from 1997 to 2006, with most biopsies (86.4%) taken
between 2001 and 2006. Of the participants 92% attended
theoutpatients’departmentofageneralendocrineclinicand
8% were hospitalized patients. The indication for biopsy was
the presence of at least one solid or mixed nodule detected by
ultrasound examination. Cystic lesions with a diameter over
10mm, or less than 10mm but suspicious for malignancy
(papilliferous proliferations etc.), were also punctured and
aspirated.
All patients had their ﬁrst UG-FNAB. Patients with
subsequent UG-FNAB due to inconclusive specimens were
not included in this study population. All patients signed an
informed consent before the procedure.
In this study, all FNAB were ultrasound-guided (the
diﬀerent techniques for UG-FNAB are reviewed in [21, 22])
and a linear transducer 7.5MHz (Fukuda 5500, Japan) was
used.Patientsreceivednoanestheticandwereinthestandard
supine position during the intervention. We used a “free
hand” technique with a parallel approach, needles of 20
and 22G and syringes of 10cc. Almost all of the nodules
(except the smallest) were punctured at least twice. We only
used nonaspiration (capillary) biopsy in a few cases (8%)
when the aspirate in two consecutive punctures of one and
the same nodule was obviously blood. The smears were
dried for 24 hours at room temperature and then processed
withPappenheimstaining.Cytologicalanalysiswasroutinely
performed by a specialist experienced in thyroid pathology.
For the purposes of this analysis the ﬁndings were divided
into 5 main groups: malignant, adenoma, MNG, inconclu-
sive, and others. Moreover, the ultrasound category MNG
and its cytological presentation were split in “benign” and
“malignant” subcategories. Further, malignant lesions were
diﬀerentiated into diﬀerent cytological subgroups (Table 1).
Other parallel ﬁndings were also recorded, but are not an
object of this particular analysis.
Thecomparisonbetweenultrasonography(U)andcytol-
ogy (C) ﬁndings was made as follows. The results obtained
by both methods were divided into malignant (including
“probably malignant”, “suspicious for malignancy” etc.) =
positive (U+ and C+) and most likely nonmalignant =
negative (U− and C−). Further, we considered U+C+ as
true positive (TP), U+C− as false positive (FP), U−C−
as true negative (TN) and U−C+ as false negative (FN).
We calculated the sensitivity = TP/(TP+FN), speciﬁcity
= TN/(TN+FP), positive predictive value = TP/(TP+FP),
negative predictive value = TN/(TN+FN), and diagnostic
accuracy = (TP+TN)/(FP+FN+TP+TN). Patients with two
diﬀerent ﬁndings in diﬀerent nodules were given a special
category. The main question that this invasive diagnostic
method is designed to answer is “malignant or not?”. We
considered the US diagnoses (adenoma/multinodular goiter
or probably malignant) that corresponded to the diagnoses
from cytology to be coincidental, independent of the addi-
tional cytological ﬁnding. For example, a patient with 3
nodules and US diagnosis, that is, multinodular goiter, was
interpreted as coincidental, but if one of these 3 nodules was
malignant, we considered this was not coincidental with the
cytology. The terms adenomatous goiter, nontoxic nodular
goiter, and colloid nodular goiter are used interchangeably as
descriptive terms when a multinodular goiter is found [23].
Where possible, the comparison between cytology (C)
andﬁnalhistology(H)resultswascalculatedinthesameway
in those patients who had been operated on. If records in
our registry were lacking, we tried to contact all of the C+
patients to obtain information if his/her thyroid had been
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Figure 2: Distribution by size of the punctured nodules.
unable to obtain data for these comparisons in most of the
outpatients with negative cytology results, because this was a
retrospective study performed in an endocrine department,
and these patients were not operated on and lost to followup.
2.1. Statistical Methods. Exploratory analysis was per-
formed including graphical presentation of distribution
and usual descriptive statistics. Diﬀerence between two
proportions tests were applied for sensitivity, speciﬁcity,
positive and negative predictive values, diagnostic accuracy
and C+malignancy rate. Diﬀerences between solitary and
MNG cases were tested. The P-level values ware computed
based on the t-values for the respective statistics. Both one-
sided and two-sided tests were performed. The diﬀerences
were considered signiﬁcant at P<0.05. The computations
were performed by STATISTICA (data analysis software
system StatSoft, Inc., version 5.5).
3. Results
From the 359 patient records studied 29 were excluded
because of insuﬃcient information in the US-exam records.
Theremaining330patientsincluded306womenand24men
(12.8:1). The mean age ± SD was 48.4 ± 11.2 years ranging
from 16 to 84 years (Figure 1).
A total of 596 nodules were found by ultrasound. UG-
FNAB was performed on 546 nodules (91.6%). In most cases
of MNG, only the three biggest nodules were punctured.
The total number of punctures was 1231, representing 2.3
punctures per nodule and 3.7 punctures per patient.
The volume of the nodule could not be calculated from
all records, and we used the longest registered diameter for






























































Figure 3: Distribution by size of the malignant nodules.
From the 330 patients with 546 punctured nodules 16
patients (4.8%) with 18 nodules were excluded after cytology
becauseofnoninformativeresults.Another7patients(2.1%)
with 16 pseudonodules (T. Hashimoto as sole diagnosis)
were also excluded. This left data from 307 patients with
512 nodules (Table 2) for further analysis. In this group, 54
nodules in 50 patients were evaluated by US as “probably
malignant”, but this suspicion was only conﬁrmed by
cytology for 14 nodules in 12 patients. Six more cancers
were found in 6 patients who were U−.I nt o t a l ,2 0n o d u l e s
were malignant in 18 patients by cytology. One of these
patients(U+withMNG)hadbifocalcarcinoma,andanother
(U+ with MNG) had two metastases from breast cancer.
The percent of carcinomas diagnosed by cytology in this
study was 3.9% of nodules and 5.9% of patients (Table 1 and
Figure 3). Two of these 18 patients were lost to followup after
the UG-FNAB. The cytology:histology coincidence analysis
was conducted on the data from the remaining 16 patients.
From their 18 C+ nodules, 15 (83.3%) were conﬁrmed after
surgery, but 3 were not. In 13 out of the 16 C+ patients the
diagnosis was veriﬁed as H+.
The subgroup of patients with solitary nodules com-
prised 151 patients with 151 nodules. Of these 22 were U+
but only 8 were C+. From the 129 U− nodules 2 were C+.
One patient was lost to followup. The histology conﬁrmed
the diagnosis in 8 of these 9 C+ nodules (88.9%).
156 patients had MNG with a total number of 361
punctured nodules. 28 patients were U+ with 32 suspicious
nodules and 4 of them were C+ with 6 nodules. Missed by
ultrasound were 4 C+ patients and two of the malignant
noduleswerenondominant.Onepatientwaslosttofollowup
and from the 7 C+ patients with 9 nodules histology
conﬁrmed malignancy in 5 with 7 nodules (71.4% of the
patients and 77.8% of the nodules) (Table 2).
The ultrasound/cytology coincidence analyses indicated
a lower positive predictive value and diagnostic accuracy
(P<0.05) and a borderline diﬀerence in speciﬁcity (P =
0.066) for patients with solitary nodules compared to MNG.
None of the cancers was found in a pure cyst. Only one
of the cancers (papillary) was hyperechoic and only one was
lessthan5mm.Otherparallelﬁndings(37cases)included28
thyreoiditis Hashimoto, 5 thyreoiditis subacuta, 1 intrathy-
roid parathyroid adenoma, 2 candida inﬂammatory changes,
and 1 sarcoidosis.
UG-FNAB is a safe diagnostic method. We had to stop
the procedure twice because of a hypotensive reaction,4 ISRN Endocrinology
Table 2: Comparison between ultrasound, cytology, and histology results.
Nodules Patients
Total Solitary MNG Total Solitary MNG
N = 512 151 361 307 151 156
U+C+ 14 8 6 12 8 4
U+C− 40 14 26 38 14 24
U−C+ 6 2 4 6 2 4
U+C− 452 127 325 251 127 124
Sensitivity (%) 70.0 80.0 60.0 66.7 80.0 50.0
Speciﬁcity (%) 91.9 90.1 92.6 86.9 90.1 83.8
Positive predictive value (%) 25.9 36.4 18.8 24.0 36.4 14.3∗
Negative predictive value (%) 98.7 98.4 98.8 97.7 98.4 96.9
Diagnostic accuracy (%) 91.0 89.4 91.7 85.7 89.4 82.1∗
C+ malignancy rate (%) 3.9 6.6 2.7 5.9 6.6 5.1
C+H+ 15 8 7 13 8 5
C+H− 312 312
Positive predictive value (%) 83.3 88.9 77.8 81.3 88.9 71.4
P<0.05 between patients with solitary nodules and MNG.
U+ and U− ultrasound positive and negative.
C+ and C− cytology positive and negative.
H+ and H− histology positive and negative.
but no additional medication or reanimation measures
were necessary in these cases. The patients knew from the
informed consent form that they could experience some
pain after biopsy and common analgesics are appropriate
drugs in such cases. Only two patients complained of pain
after the manipulation, one of whom had a substantial
subcapsular hematoma. No additional surgical procedures
were necessary.
4. Discussion
The superﬁcial position of the thyroid is an advantage
compared to other endocrine glands and FNAB has become
a simple and reliable method for thyroid evaluation. Most
studies with FNAB have not used US guidance. Larger
nodules have tended to be detected because usually palpable
nodules are bigger than 10mm, [23]. The introduction
of real-time ultrasound guidance has greatly improved the
sensitivity and speciﬁcity of FNAB [18]. In palpable nodules,
biopsies can be obtained with more precision (1) exactly
from the targeted nodule and (2) from its more-informative
zones, which are usually peripheral, rather than central
and often necrotic areas. In heterogeneous nodules, biopsies
should be taken from the hypoechoic area of the nodule
and in cysts or mixed nodules they should be from the wall
and areas with papilliferous proliferation [21]. The “non-
diagnostic” rate decreased from 15%–20% in earlier FNAB
studies to around 3% in studies using UG-FNAB [17, 24].
This decrease is important in assessing the costeﬀectiveness
of the method. Some investigators report an even higher
eﬀectiveness of UG-FNAB with only 0.7% unsatisfactory
biopsies [25]. Our study results were inconclusive for 4.8%
of the patients and 3.3% of the nodules. Although not the
prime aim of this study, we analyzed the fate of these patients
with inconclusive ﬁrst biopsies in a separate series. Of the
16 patients 10 underwent a secondary UG-FNAB which was
suﬃcient for diagnoses in 9 (90%), but no cancer was found.
Some studies have reported no further increase in diagnostic
power of secondary biopsy [26]. Bearing in mind the low
failure rate in primary UG-FNAB and the low probability of
failure on repetition we recommend rebiopsy in such cases.
The most important advantage of UG-FNAB over FNAB
is the possibility of puncturing nonpalpable nodules (size
10–15mm or less). There is no consensus on whether
it is necessary to biopsy such nodules (incidentalomas).
Contra-arguments are that they are very common, their
prognosis, even in the case of malignancy, is not so poor,
and routine biopsy is not costeﬀective. Proarguments are
that the incidence of malignancy is the same in palpable and
nonpalpable nodules [27, 28] and such small carcinomas are
often as aggressive as larger ones [29]. In our study, 42.9 %
of the nodules were between 5 and 15mm in their greatest




cancers in this subgroup was the same as in the whole group.
Our impression is that nodules in the range 5–15mm should
be punctured because of their high malignancy potential
and the improved prognosis after surgical treatment. We are
especially rigorous in screening young patients and puncture
every solid or mixed nodule found. We adopt this approach
also for nodules less than 5mm. A physician inexperienced
in puncturing such nodules would be advised to follow up
regularly. Most of the nodules found in this study were less
than 2cm, but this could be explained by patients with larger
lesionsbeingdirectlyreferredtosurgery,accordingtotheold
rule “If a nodule is greater than 2cm it should be removed!”.
In our study, every patient who had at least one nodule
underwent UG-FNAB and a high proportion (91.6%) ofISRN Endocrinology 5
all nodules were punctured. Other specialists use narrower
indications for biopsy, but most agree that ultrasound is
not reliable enough for a solid nodule to be classiﬁed as
benign or malignant. In total, 20 carcinomas were found
(3.9% of the nodules) in our series and half of them were
in solitary nodules, which are a proper indication for UG-
FNAB [30, 31].
The decision to biopsy a MNG is more complex. The
incidence of malignancy in multinodular goitre ranges from
1% to 10% [32–35]. One study reported the sensitivity
of FNAB in MNG at only 17%, but the speciﬁcity at
96%, diagnostic accuracy at 88%, the positive predictive
value at 32% and the negative predictive value at 88%
[36]. The authors concluded that FNAB is not useful for
diﬀerentiating MNG with malignant degeneration from
benign MNG because more than 80% of carcinomas go
unnoticed, and they suggested that clinical criteria should
prevail over FNAB. Although most of the biopsies were not
ultrasound guided the study raises an important question
for the diagnostic value of this method in MNG. Our
study conﬁrmed lower positive predictive value, diagnostic
accuracyandaborderlinediﬀerenceinspeciﬁcityforpatients
with solitary nodules compared to MNG.
Inourstudy,aspeciﬁcseparateapproachfornodulesand
patients was used. We found malignancy in 10 of the nodules
in MNG (2.7%). This is about 2.4 times lower than that we
found in solitary nodules (6.6%), but this low malignancy
risk for each nodule is multiplied by the higher number
of nodules. The resulting risk for the particular patient, as
shown in this study, does not diﬀer substantially from the
risk if a solitary nodule presents.
As mentioned in “Patients and Methods”, the lack of
histological control for most of our C-patients is a serious
limitation of our study. But this is usual in an endocrinology
unit where referral of a C-patient for surgical exploration
cannot be justiﬁed. The ultrasound monitoring of these
patients is only a partial solution to the problem, especially
for small nodules, considering the slow natural evolution
of such benign, and some malignant, lesions as well as the
“adherence to the physician” factor. Core biopsy is another
way of improving the diagnostic value of this method, but it
is more expensive and still not as popular as conventional
UG-FNAB. Another possibility is to biopsy most of the
nodules in a MNG and to obtain more samples for each
nodule (2.3 in this study). The reasoning and considerations
for such an approach are the following.
(1) Although very probable, carcinomas are not always
located in the dominant nodule, which is punctured
most often. Taking samples from other nodules
increases the chances of diagnosing an occult malig-
nant process. In our study, two of the malignant
nodules in MNG were not suspected from ultra-
sonography and were nondominant.
(2) In some cases, the US and surgical reports are not
topographically consistent, and it is uncertain if a
particular nodule that has or has been not punctured
is the malignant nodule found by surgery. Such
artiﬁcial lack of coincidence could interfere with the
statistical evaluation indices.
(3) Perioperative complications, postoperative state and
treatment indications, and the probability of relapse
are also arguments to be considered.
(4) The ﬁnal decision for regular US monitoring, UG-
FNAB of the dominant nodule, multinodule, and
multipuncture UG-FNAB or surgical exploration,
especially in a patient whose MNG is not obviously
suspicious for malignancy and/or very large, is an
economic one. UG-FNAB and US followup is less
expensive than surgery. Measurement of each nodule
on every consecutive visit is not always accurate
enough and is time consuming. If a biopsy has been
performed, the interval between the visits could be
longer, saving time and money of the health care
system, without decreasing the medical vigilance.
The endemic aspects of MNG should be taken into
consideration as well.
In our series, no cancer was found in a pure cyst and
only one was hyperechoic. We agree with the conclusion
drawn by Leenhardt et al. [37], who analysed 450 non-
palpable nodules, that cystic and hyperechoic nodules are
not indications for UG-FNAB (nevertheless cysts are often
punctured and aspirated for diagnostic and/or treatment
reasons). In patients with more than one nodule only the
FNAB on the largest one was retained in their study. They
estimated a cytological malignancy of 5%, suspicious 11%
andafterexcludingthepatientslosttofollowupahistological
malignancy rate of 4%. Bearing in mind the high percentage
of unsuspected cancers in nondominant nodules, we suggest
that most nodules should be punctured in a MNG.
The rate of the carcinomas in our study is less than
that reported by others. The reasons for this could be the
unselected population. Almost all nodules were punctured.
In most other studies, especially those originating from
surgical or morphological departments, nodules that are
punctured are the preselected ones found suspicious at the
clinical and US level, which increases the cancer probability.
5. Conclusions
UG-FNAB is a safe and reliable diagnostic approach for
thyroid nodules. It is the method of choice for hypo-
and isoechoic not purely cystic solitary nodules, regardless
of the nodule size. In MNG, its positive predictive value
and diagnostic accuracy are lower. The ﬁnal decision for
regular US monitoring, UG-FNAB of the dominant nodule,
multipuncture UG-FNAB or surgical exploration is one of
complex appraisal. We consider UG-FNAB appropriate for
most nodules in MNG according to the above-mentioned
criteria.
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